Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Cancer Gene Ther. 2013 Sep 20;20(11):642–649. doi: 10.1038/cgt.2013.56

Table 4.

Patient Follow Up and Overall Survival

Patient Late toxicities Prostate Cancer Status Survival Status Overall Survival (Years)
A1 None NED Alive 12.6
A2 None Slow PSA rise, metastatic workup neg Died of AMI 12.3
A3 None NED Died of esophageal cancer 9.9
A4 None NED Alive 13.2
A6 None NED Died of AMI 6.7
A7 None Slow PSA rise, metastatic workup neg Alive 12.4
A8 None NED Alive 10.7
A9 None Slow PSA rise on ADT, metastatic workup neg Alive 11.1
A10 None NED Alive 10.3

NED- no evidence of disease, ADT- androgen deprivation therapy, AMI- acute myocardial infarction